{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-299942","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.556069+00:00","generated_at":"2026-06-07T09:58:34.919273+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha grants ~5.3M options and RSUs to top executives; adopts 4M-share inducement plan","bullets":["CEO Sean Nolan receives 1,184,688 options and 1,184,688 RSUs (total ~2.37M shares).","President & Head of R&D Sukumar Nagendran receives 863,617 options and 863,617 RSUs.","CFO Kamran Alam receives 590,413 options and 590,413 RSUs.","Options vest 25% at 1 year, then monthly over 3 years; RSUs vest equally over 4 years.","Board adopted 2023 Inducement Plan reserving 4M shares for new-hire grants under Nasdaq Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-299942","json":"https://secwatch.observer/filing/0001193125-23-299942.json","markdown":"https://secwatch.observer/filing/0001193125-23-299942.md","text":"https://secwatch.observer/filing/0001193125-23-299942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523299942/0001193125-23-299942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523299942/d574908d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:58:34.919273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}